GTB-3550 is fusion protein comprising two anti-CD16 and anti-CD33 scFv flanking human IL-15, which showed increased efficacy in vivo in an AML model compared to the corresponding BiKE without IL-15, and prolonged persistence of human NK cells [128]. This evidence concerns the gene FCGR3A and acute myeloid leukemia.